The private-credit arm of Guggenheim Investments has employed a novel tool to attract institutional investors to its newest fund as it contends with fierce fundraising competition from other ...
DAVOS, Switzerland (Reuters) - Guggenheim Partners' chief investment officer forecast on Monday that the U.S. Federal Reserve is likely to cut interest rates roughly every quarter in 2025 ...
Confluent (NASDAQ:CFLT – Get Free Report) had its price target boosted by investment analysts at Guggenheim from $35.00 to $38.00 in a note issued to investors on Wednesday,Benzinga reports. The firm ...
Investment-grade corporates were down to 16% by the end of the year, while the team more than halved the combined high-yield and bank-loan weighting to 3%. Former Guggenheim global CIO Scott ...
Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to ...
Hosted on MSN22d
Guggenheim raises Immunovant stock target to $46, maintains BuyGuggenheim has outlined four major scenarios ... In other recent news, Piper Sandler, a prominent investment bank, has provided an update on potential catalysts for biotechnology companies up ...
Guggenheim adjusted its outlook for New York Times Company (NYSE:NYT), reducing the price target from $55.00 to $52.00 while maintaining a Neutral rating on the stock. According to InvestingPro data, ...
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution ...
In a report released today, Michael Morris from Guggenheim maintained a Buy rating on Meta Platforms (META – Research Report), with a price ...
Consult a professional regarding your specific legal or tax matters. Guggenheim Investments is the global asset management and investment advisory division of Guggenheim Partners, LLC ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results